公开(公告)号：JP2012031178A

公开(公告)日：2012-02-16

申请号：JP2011188635

申请日：2011-08-31

Applicant: Abbott Lab ,  アボット・ラボラトリーズAbbott Laboratories

Inventor： COLLINSON ALBERT ,  GHAYUR TARIQ ,  AVGERINOS GEORGE ,  DIXON RICHARD ,  KAYMAKCALAN ZEHRA

IPC: C07K16/24 ,  G01N33/50 ,  A61K39/395 ,  A61K47/48 ,  A61K49/00 ,  A61P1/04 ,  A61P17/06 ,  A61P25/00 ,  A61P29/00 ,  A61P37/06 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12N15/09 ,  C12N15/13 ,  C12P21/08 ,  G01N33/15 ,  G01N33/53 ,  G01N33/68

CPC classification number: C07K16/245 ,  A61K47/6845 ,  A61K2039/505 ,  C07K14/545 ,  C07K16/46 ,  C07K16/468 ,  C07K2317/10 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/76 ,  G01N33/6869

Abstract: PROBLEM TO BE SOLVED: To provide antibodies having dual specificity for two different but structurally related antigens.SOLUTION: The antibodies have dual specificity for IL-1α and IL-1β and neutralize IL-1α and IL-1β activity in vitro and in vivo. The antibody is a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using the antibodies are also provided.

Abstract translation: 要解决的问题：提供对两种不同但结构相关的抗原具有双重特异性的抗体。 解决方案：抗体对IL-1α和IL-1β具有双重特异性，并在体外和体内中和IL-1α和IL-1β活性。 抗体是全长抗体或其抗原结合部分。 还提供了制备方法和使用抗体的方法。 版权所有（C）2012，JPO＆INPIT

公开(公告)号：WO0202773A3

公开(公告)日：2002-08-22

申请号：PCT/US0120755

申请日：2001-06-28

Applicant: ABBOTT LAB ,  COLLINSON ALBERT ,  GHAYUR TARIQ ,  AVGERINOS GEORGE ,  DIXON RICHARD ,  KAYMAKCALAN ZEHRA

Inventor： COLLINSON ALBERT ,  GHAYUR TARIQ ,  AVGERINOS GEORGE ,  DIXON RICHARD ,  KAYMAKCALAN ZEHRA

IPC: G01N33/50 ,  A61K39/395 ,  A61K47/48 ,  A61K49/00 ,  A61P1/04 ,  A61P17/06 ,  A61P25/00 ,  A61P29/00 ,  A61P37/06 ,  C07K16/24 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12N15/09 ,  C12N15/13 ,  C12P21/08 ,  G01N33/15 ,  G01N33/53 ,  G01N33/68 ,  A61K51/10 ,  C12N15/63 ,  G01N33/577

CPC classification number: C07K16/245 ,  A61K47/6845 ,  A61K2039/505 ,  C07K14/545 ,  C07K16/46 ,  C07K16/468 ,  C07K2317/10 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/76 ,  G01N33/6869

Abstract: Antibodies having dual specificity for two different but structurally related antigens are provided. The antibodies can be, for example, entirely human antibodies, recombinant antibodies, or monoclonal antibodies. Preferred antibodies have dual specificity for IL-1 alpha and IL-1 beta and neutralize IL-1 alpha and IL-1 beta activity in vitro and in vivo . An antibody of the inventi on can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting two different but structurally related antigens (e.g., IL-1 alpha and IL-1 beta ) and for inhibiting the activity of the antigens, (e.g., in a human subject suffering from a disorder in which IL-1 alpha and/or IL-1 beta activity is detrimental.

Abstract translation: 提供了对两种不同但结构相关抗原具有双重特异性的抗体。 抗体可以是例如完全是人抗体，重组抗体或单克隆抗体。 优选的抗体对IL-1α和IL-1β具有双重特异性，并在体外和体内中和IL-1α和IL-1β活性。 本发明的抗体可以是全长抗体或其抗原结合部分。 还提供了制备方法和使用本发明抗体的方法。 本发明的抗体或抗体部分可用于检测两种不同但结构相关的抗原（例如，IL-1α和IL-1β）并用于抑制抗原的活性（例如，在受试者的受试者中 来自其中IL-1α和/或IL-1β活性是有害的病症。

公开(公告)号：CA2411374C

公开(公告)日：2012-10-30

申请号：CA2411374

申请日：2001-06-28

Applicant: ABBOTT LAB

Inventor： COLLINSON ALBERT ,  GHAYUR TARIQ ,  AVGERINOS GEORGE ,  DIXON RICHARD ,  KAYMAKCALAN ZEHRA

IPC: C12N15/13 ,  G01N33/50 ,  A01K67/027 ,  A61K39/395 ,  A61K47/48 ,  A61K49/00 ,  A61K51/10 ,  A61P1/04 ,  A61P17/06 ,  A61P25/00 ,  A61P29/00 ,  A61P37/06 ,  C07K14/545 ,  C07K16/24 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12N15/09 ,  C12N15/63 ,  C12P21/08 ,  G01N33/15 ,  G01N33/53 ,  G01N33/577 ,  G01N33/68

Abstract: Antibodies having dual specificity for two different but structurally related antigens are provided. The antibodies can be, for example, entirely human antibodies, recombinant antibodies, or monoclonal antibodies. Preferred antibodies have dual specificity for IL-1.alpha. and IL-1.beta. and neutralize IL-1.alpha. and IL-1.beta. activity in vitroand in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting two different but structurally related antigens (e.g., IL-1.alpha. and IL-1.beta.) and for inhibiting the activity of the antigens, (e.g., in a human subject suffering from a disorder in which IL-1.alpha. and/or IL-1.beta. activity is detrimental.

公开(公告)号：BG66209B1

公开(公告)日：2012-04-30

申请号：BG10748303

申请日：2003-01-21

Applicant: ABBOTT LAB

Inventor： COLLINSON ALBERT ,  GHAYUR TARIQ ,  AVGERINOS GEORGE ,  DIXON RICHARD ,  KAYMAKCALAN ZEHRA

IPC: C12N15/13 ,  G01N33/50 ,  A61K39/395 ,  A61K47/48 ,  A61K49/00 ,  A61K51/10 ,  A61P1/04 ,  A61P17/06 ,  A61P25/00 ,  A61P29/00 ,  A61P37/06 ,  C07K16/24 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12N15/09 ,  C12P21/08 ,  G01N33/15 ,  G01N33/53 ,  G01N33/577 ,  G01N33/68

Abstract: Предоставятсеметодизаполучаваненаантителас двойнаспецифичностсъгласноизобретението. Антителатаилиучастъцитенаантителасъгласноизобретениетосеизползватзаоткриваненадваразлични, ноструктурносвързаниантигена (например IL-1алфаи IL-1бета) изаинхибираненаактивносттанаантигените (напримерприсубектчовек, страдащотнарушение, прикоетосеопределя IL-1алфаи/или IL-1бетаактивността.

公开(公告)号：NZ523080A

公开(公告)日：2004-11-26

申请号：NZ52308001

申请日：2001-06-28

Applicant: ABBOTT LAB

Inventor： COLLINSON ALBERT ,  GHAYUR TARIQ ,  AVGERINOS GEORGE ,  DIXON RICHARD ,  KAYMAKCALAN ZEHRA

IPC: G01N33/50 ,  A61K39/395 ,  A61K47/48 ,  A61K49/00 ,  A61P1/04 ,  A61P17/06 ,  A61P25/00 ,  A61P29/00 ,  A61P37/06 ,  C07K16/24 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12N15/09 ,  C12N15/13 ,  C12P21/08 ,  G01N33/15 ,  G01N33/53 ,  G01N33/68 ,  G01N33/577 ,  A61K51/10 ,  C12N15/63

Abstract: A dual-specificity antibody or antigen-binding portion thereof specifically binds interleukin-1alpha and interleukin-1beta wherein the antibody is not a fully mouse antibody. The antibody can be used in diagnostic methods for detecting IL-á or IL-â and in the manufacture of a medicament for treating interlauikin-1-related disorders such as inflammatory disorder, autoimmune disorder i.e. rheumatoid arthritis, Crohn's disease, multiple sclerosis, insulin dependant diabetes mellitus and psoriasis. Methods of obtaining dual-specificity antibodies and methods of making an antibody are also described.

公开(公告)号：PL359995A1

公开(公告)日：2004-09-06

申请号：PL35999501

申请日：2001-06-28

Applicant: ABBOTT LAB

Inventor： COLLINSON ALBERT ,  GHAYUR TARIQ ,  AVGERINOS GEORGE ,  DIXON RICHARD ,  KAYMAKCALAN ZEHRA

IPC: G01N33/50 ,  A61K39/395 ,  A61K47/48 ,  A61K49/00 ,  A61P1/04 ,  A61P17/06 ,  A61P25/00 ,  A61P29/00 ,  A61P37/06 ,  C07K16/24 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12N15/09 ,  C12N15/13 ,  C12P21/08 ,  G01N33/15 ,  G01N33/53 ,  G01N33/68 ,  A61K51/10

Abstract: Antibodies having dual specificity for two different but structurally related antigens are provided. The antibodies can be, for example, entirely human antibodies, recombinant antibodies, or monoclonal antibodies. Preferred antibodies have dual specificity for IL-1 alpha and IL-1 beta and neutralize IL-1 alpha and IL-1 beta activity in vitro and in vivo. The antibody can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using these antibodies are also provided. These antibodies, or antibody portions, are useful for detecting two different but structurally related antigens (e.g., IL-1 alpha and IL-1 beta) and for inhibiting the activity of the antigens, (e.g., in a human subject suffering from a disorder in which IL-1 alpha and/or IL-1 beta activity is detrimental.

公开(公告)号：SK284040B6

公开(公告)日：2004-08-03

申请号：SK106298

申请日：1997-02-10

Applicant: ABBOTT LAB BERMUDA LTD

Inventor： SALFELD JOCHEN G ,  ALLEN DEBORAH J ,  KAYMAKCALAN ZEHRA ,  LABKOVSKY BORIS ,  MANKOVICH JOHN A ,  MCGUINNESS BRIAN T ,  ROBERTS ANDREW J ,  SAKORAFAS PAUL ,  HOOGENBOOM HENDRICUS R J M ,  SCHOENHAUT DAVID ,  VAUGHAN TRISTAN J ,  WHITE MICHAEL ,  WILTON ALISON J

IPC: C12N15/09 ,  A61K31/00 ,  A61K31/40 ,  A61K31/403 ,  A61K31/404 ,  A61K31/415 ,  A61K31/4164 ,  A61K31/4178 ,  A61K31/505 ,  A61K31/517 ,  A61K31/52 ,  A61K31/529 ,  A61K31/57 ,  A61K31/573 ,  A61K31/675 ,  A61K38/00 ,  A61K38/04 ,  A61K38/16 ,  A61K39/39 ,  A61K39/395 ,  A61P1/00 ,  A61P1/04 ,  A61P1/16 ,  A61P3/10 ,  A61P7/00 ,  A61P7/04 ,  A61P9/00 ,  A61P9/04 ,  A61P9/10 ,  A61P11/00 ,  A61P11/16 ,  A61P13/12 ,  A61P17/00 ,  A61P17/02 ,  A61P19/02 ,  A61P19/06 ,  A61P25/00 ,  A61P27/02 ,  A61P29/02 ,  A61P31/00 ,  A61P31/04 ,  A61P31/12 ,  A61P31/18 ,  A61P33/06 ,  A61P35/00 ,  A61P35/04 ,  A61P37/00 ,  A61P37/02 ,  A61P37/06 ,  A61P37/08 ,  A61P39/02 ,  C07K16/24 ,  C12N1/21 ,  C12N5/10 ,  C12P21/08 ,  G01N33/53 ,  G01N33/543 ,  G01N33/564 ,  G01N33/576 ,  G01N33/68 ,  C12N15/13 ,  C12N15/64

Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor 'alpha' (hTNF'alpha') are disclosed. These antibodies have high affinity for hTNF'alpha'(e.g., Kd = 10exp(-8) M or less), a slow off rate for hTNF'alpha' dissociation (e.g., Koff = 10exp(-3) sec-1 or less) and neutralize hTNF'alpha' activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hTNF'alpha' and for inhibiting hTNF'alpha' activity, e.g., in a human subject suffering from a disorder in which hTNF'alpha' activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.

公开(公告)号：CZ20030291A3

公开(公告)日：2003-05-14

申请号：CZ20030291

申请日：2001-06-28

Applicant: ABBOTT LAB

Inventor： COLLINSON ALBERT ,  GHAYUR TARIQ ,  AVGERINOS GEORGE ,  DIXON RICHARD ,  KAYMAKCALAN ZEHRA

IPC: G01N33/50 ,  A61K39/395 ,  A61K47/48 ,  A61K49/00 ,  A61P1/04 ,  A61P17/06 ,  A61P25/00 ,  A61P29/00 ,  A61P37/06 ,  C07K16/24 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12N15/09 ,  C12N15/13 ,  C12P21/08 ,  G01N33/15 ,  G01N33/53 ,  G01N33/68 ,  A61K51/10 ,  C12N15/63 ,  G01N33/577

CPC classification number: C07K16/245 ,  A61K47/6845 ,  A61K2039/505 ,  C07K14/545 ,  C07K16/46 ,  C07K16/468 ,  C07K2317/10 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/76 ,  G01N33/6869

公开(公告)号：NO20026239D0

公开(公告)日：2002-12-27

申请号：NO20026239

申请日：2002-12-27

Applicant: ABBOTT LAB

Inventor： COLLINSON ALBERT ,  GHAYUR TARIQ ,  AVGERINOS GEORGE ,  DIXON RICHARD WOODWARD ,  KAYMAKCALAN ZEHRA

IPC: G01N33/50 ,  A61K39/395 ,  A61K47/48 ,  A61K49/00 ,  A61P1/04 ,  A61P17/06 ,  A61P25/00 ,  A61P29/00 ,  A61P37/06 ,  C07K16/24 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12N15/09 ,  C12N15/13 ,  C12P21/08 ,  G01N33/15 ,  G01N33/53 ,  G01N33/68 ,  C12N

Abstract: Antibodies having dual specificity for two different but structurally related antigens are provided. The antibodies can be, for example, entirely human antibodies, recombinant antibodies, or monoclonal antibodies. Preferred antibodies have dual specificity for IL-1 alpha and IL-1 beta and neutralize IL-1 alpha and IL-1 beta activity in vitro and in vivo. The antibody can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using these antibodies are also provided. These antibodies, or antibody portions, are useful for detecting two different but structurally related antigens (e.g., IL-1 alpha and IL-1 beta) and for inhibiting the activity of the antigens, (e.g., in a human subject suffering from a disorder in which IL-1 alpha and/or IL-1 beta activity is detrimental.

公开(公告)号：PE01322002A1

公开(公告)日：2002-03-04

申请号：PE0006412001

申请日：2001-06-28

Applicant: ABBOTT LAB

Inventor： AVGERINOS GEORGE ,  COLLINSON ALBERT ,  GHAYUR TARIQ ,  KAYMAKCALAN ZEHRA ,  DIXON RICHARD

IPC: G01N33/50 ,  A01K67/027 ,  A61K39/395 ,  A61K47/48 ,  A61K49/00 ,  A61K51/10 ,  A61P1/04 ,  A61P17/06 ,  A61P25/00 ,  A61P29/00 ,  A61P37/06 ,  C07K14/545 ,  C07K16/24 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12N15/09 ,  C12N15/13 ,  C12N15/63 ,  C12P21/08 ,  G01N33/15 ,  G01N33/53 ,  G01N33/577 ,  G01N33/68

CPC classification number: C07K16/245 ,  A61K47/6845 ,  A61K2039/505 ,  C07K14/545 ,  C07K16/46 ,  C07K16/468 ,  C07K2317/10 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/76 ,  G01N33/6869

Abstract: SE REFIERE A UN ANTICUERPO DE ESPECIFIDAD DOBLE O UNA PORCION DEL MISMO DE UNION A ANTIGENO CARACTERIZADO PORQUE SE UNE A LA INTERLEUQUINA 1a Y INTERLUQUINA-1b CON UNA CONSTANTE DE VELOCIDAD Koff DE 0,1s-1 O MENOS O QUE INHIBE LA ACTIVIDAD DE INTERLEUQUINA-1a CON UNA IC50 DE 1*10-5 O MENOS. TAMBIEN SE REFIERE A UN METODO PARA OBTENER UN ANTICUERPO DE ESPECIFICIDAD DOBLE QUE SE UNE ESPECIFICAMENTE A INTERLEUQUINA-1a Y INTERLEUQUINA-1b O DOS MOLECULAS DIFERENTES PERO RELACIONADAS DESDE EL PUNTO DE VISTA ESTRUCTURAL QUE COMPRENDE PROVEER UN ANTIGENO CON UNA CARACTERISTICA ESTRUCTURAL COMUN DE IL-1a E IL-1b; EXPONER UN REPERTORIO DE ANTICUERPOS AL ANTIGENO IN VIVO INMUNIZANDO AL ANIMAL O PONER EN CONTACTO LA MUESTRA O TEJIDO BIOLOGICO SOSPECHADO DE CONTENER IL-1a E IL-1b CON EL ANTICUERPO DE ESPECIFICIDAD DOBLE